Alnylam Pharmaceuticals | ALNY - Creditori Commerciali

Prezzo Delle Azioni
301.30
Cambio Giornaliero
-0.81 -0.27%
Mensile
-4.68%
Annuale
14.46%
Q2 Previsione
299.00




Creditori Commerciali Cambiamento Data
Acadia Pharmaceuticals USD 10.9M 10.84M 2025-12
Agios Pharmaceuticals USD 13.75M 4.61M 2026-03
Alnylam Pharmaceuticals USD 115.72M 1.87M 2025-12
Amgen USD 20.89B 1.25B 2025-12
Arrowhead Research USD 32.94M 15.26M 2025-12
BioCryst Pharmaceuticals USD 15.83M 10.26M 2025-12
BioMarin Pharmaceutical USD 759.03M 39.41M 2025-12
Incyte USD 228.62M 1.41B 2026-03
Ionis Pharmaceuticals USD 26.03M 2.05M 2026-03
Moderna USD 317M 50M 2025-12
Neurocrine Biosciences USD 545.5M 425.6M 2025-12
Novartis USD 4.46B 99M 2025-12
PTC Therapeutics USD 45.49M 8.87M 2025-12
Regeneron Pharmaceuticals USD 1.03B 4.81B 2026-03
Sangamo BioSciences USD 10.74M 7.46M 2025-06
Sanofi EUR 22.93B 2.89B 2025-12
Sarepta Therapeutics USD 280.84M 186.83M 2025-12
Takeda JPY 467.59B 28.61B 2025-12
Tectonic Therapeutic USD 1.09M 392K 2025-12
Ultragenyx Pharmaceutical USD 40.57M 6.33M 2025-09
Vertex Pharmaceuticals USD 3.43B 600.9M 2025-12
Xencor USD 10.83M 1.75M 2025-12